Publications
Learn about the research supporting our preclinical and clinical development programs.
Publications
February 15, 2019 Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors
AACR Journals
June 6, 2018 Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics
ADMET
March 8, 2018 Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema
Journal of Medicinal Chemistry
July 1, 2012 Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases
ChemMedChem
May 31, 2009 Phage-encoded combinatorial chemical libraries based on bicyclic peptides
Nature Chem Bio
Presentations
SITC
November 9, 2019
A novel fully synthetic dual targeted EphA2/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism
November 9, 2019
A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism
November 6, 2019
A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 29, 2019
BT8009, a Bicycle® Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models.
October 29, 2019
BT5528, a Bicycle Toxin Conjugate targeting EphA2: mechanism of action and clinical translation
World ADC Congress 2019
October 11, 2019
BT5528, an EphA2-targeting Bicycle® Toxin Conjugate
The European Society of Medical Oncology 2019 Annual Congress
30th Symposium on Medicinal Chemistry
6th Annual Peptides Congress
ELRIG Research & Innovation
April 3, 2019
Bicycles® - An entirely new class of therapeutics
AACR
April 2, 2019
Activation of 4-1BB using multivalent and tumour targeted bicyclic peptides
April 2, 2019
BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models
9th Annual World ADC Conference
2018
